Vaxcyte, Inc. (NASDAQ:PCVX) Holdings Cut by Novo Holdings A S

Novo Holdings A S trimmed its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 21.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 750,000 shares of the company’s stock after selling 200,000 shares during the quarter. Vaxcyte makes up approximately 4.3% of Novo Holdings A S’s investment portfolio, making the stock its 8th biggest holding. Novo Holdings A S’s holdings in Vaxcyte were worth $85,702,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Riverview Trust Co purchased a new stake in Vaxcyte in the third quarter valued at approximately $27,000. Fifth Third Bancorp purchased a new stake in shares of Vaxcyte in the second quarter valued at about $35,000. Fidelis Capital Partners LLC purchased a new stake in shares of Vaxcyte in the first quarter valued at about $37,000. Blue Trust Inc. boosted its stake in Vaxcyte by 33.5% during the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after buying an additional 93 shares during the period. Finally, J.Safra Asset Management Corp boosted its stake in Vaxcyte by 649.4% during the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock worth $46,000 after buying an additional 526 shares during the period. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Leerink Partners increased their target price on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 3rd. BTIG Research increased their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Jefferies Financial Group increased their target price on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Bank of America increased their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Finally, Mizuho increased their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 10th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $147.50.

Insiders Place Their Bets

In other news, CFO Andrew Guggenhime sold 42,000 shares of Vaxcyte stock in a transaction on Friday, October 18th. The shares were sold at an average price of $115.39, for a total value of $4,846,380.00. Following the transaction, the chief financial officer now directly owns 90,383 shares of the company’s stock, valued at $10,429,294.37. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, SVP Elvia Cowan sold 5,000 shares of Vaxcyte stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total value of $538,350.00. Following the transaction, the senior vice president now directly owns 12,723 shares of the company’s stock, valued at $1,369,885.41. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Andrew Guggenhime sold 42,000 shares of Vaxcyte stock in a transaction on Friday, October 18th. The shares were sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the completion of the transaction, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,429,294.37. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 92,098 shares of company stock valued at $9,937,773. 3.10% of the stock is owned by corporate insiders.

Vaxcyte Trading Up 0.6 %

Vaxcyte stock opened at $112.94 on Friday. The company has a fifty day simple moving average of $106.09 and a 200-day simple moving average of $84.30. The stock has a market cap of $12.29 billion, a P/E ratio of -26.39 and a beta of 0.99. Vaxcyte, Inc. has a 12-month low of $45.61 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.04. During the same quarter last year, the firm posted ($0.70) EPS. As a group, sell-side analysts forecast that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.